Co-Authors
This is a "connection" page, showing publications co-authored by TITO R MENDOZA and LORETTA A WILLIAMS.
Connection Strength
2.195
-
Measuring symptom burden in patients with cancer during a pandemic: the MD Anderson symptom inventory for COVID-19 (MDASI-COVID). J Patient Rep Outcomes. 2023 05 26; 7(1):48.
Score: 0.235
-
Development and Validation of a Patient-reported Outcome Measure for Gastrointestinal Obstruction in the Setting of Advanced Malignancy. Ann Surg. 2022 Dec 01; 276(6):e805-e811.
Score: 0.199
-
The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. J Patient Rep Outcomes. 2020 Feb 19; 4(1):15.
Score: 0.187
-
Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). J Patient Rep Outcomes. 2019 Jun 17; 3(1):34.
Score: 0.179
-
Assessment of baseline symptom burden in treatment-na?ve patients with lung cancer: an observational study. Support Care Cancer. 2019 Sep; 27(9):3439-3447.
Score: 0.174
-
Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Qual Life Res. 2018 Dec; 27(12):3229-3241.
Score: 0.169
-
Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer. 2019 Mar; 27(3):1021-1028.
Score: 0.168
-
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain. 2015 Oct; 16(10):1032-43.
Score: 0.136
-
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013 Aug 01; 122(5):641-7.
Score: 0.118
-
Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. J Hematol Oncol. 2013 Feb 05; 6:13.
Score: 0.115
-
Trans-pacific multicenter collaborative study of minimally invasive proximal versus total gastrectomy for proximal gastric and gastroesophageal junction cancers. BMC Surg. 2023 Sep 01; 23(1):262.
Score: 0.060
-
Symptom Burden in Patients with Malignant Bowel Obstruction Treated With or Without Surgery. J Am Coll Surg. 2023 03 01; 236(3):514-522.
Score: 0.057
-
Identification of Breast Cancer Survivors With High Symptom Burden. Cancer Nurs. 2022 Jul-Aug 01; 45(4):253-261.
Score: 0.053
-
Percutaneous Cordotomy for Pain Palliation in Advanced Cancer: A Randomized Clinical Trial Study Protocol. Neurosurgery. 2020 08 01; 87(2):394-402.
Score: 0.048
-
What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 10; 16(10):e1151-e1160.
Score: 0.048
-
Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35.
Score: 0.035
-
Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.
Score: 0.034
-
Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46.
Score: 0.033
-
Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41.
Score: 0.033
-
Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.
Score: 0.031
-
Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecol Oncol. 2013 Aug; 130(2):323-8.
Score: 0.029
-
Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemother Pharmacol. 2013 Jun; 71(6):1531-40.
Score: 0.029
-
Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010 Apr 15; 116(8):2053-63.
Score: 0.024